Cyclosporine Market Size – By Indication, By Dosage Form, By Route of Administration, By Distribution Channel, Global Forecast, 2025 – 2034

Cyclosporine Market Size

The global cyclosporine market size was valued at USD 3.3 billion in 2024 and is estimated to grow at a CAGR of 14.5% from 2025 to 2034. The growth of the market is driven by increasing demand for organ transplantation procedures.
 

For instance, as per the United Network for Organ Sharing, a total of 46,632 organ transplants were performed in 2023, marking an 8.7% increase from 2022 and a 12.7% increase from 2021. As cyclosporine is a critical immunosuppressant used to prevent organ rejection, with growing number of organ transplantation procedures, the demand for cyclosporine is rising, thus supporting market growth.
 

Additionally, rising prevalence of autoimmune disorders, such as rheumatoid arthritis and psoriasis, has further fueled the demand for cyclosporine as a therapeutic agent. Moreover, expanding healthcare access in emerging economies, coupled with increasing investment in research and development for immunosuppressive therapies, supports the market's expansion. Growing awareness about organ donation and advancements in transplant technologies also bolster the cyclosporine market globally.
 

Cyclosporine is an immunosuppressive drug primarily used to prevent organ rejection in transplant recipients and to treat certain autoimmune disorders. It works by inhibiting the activity of T-lymphocytes, which play a central role in immune responses. Cyclosporine is commonly prescribed for kidney, liver, and heart transplant patients to reduce the risk of graft rejection. Beyond transplantation, it is also used in treating conditions like rheumatoid arthritis, psoriasis, and certain ophthalmic disorders such as dry eye disease.
 

Cyclosporine Market Trends

The growing prevalence of autoimmune diseases is a significant driver of the market.
 

• As per the Institute for Health Metrics and Evaluation, as of 2020, approximately 17.6 million people worldwide were estimated to have rheumatoid arthritis. By 2050, it is forecasted that the number of individuals living with RA could rise to 31.7 million globally. Similarly, approximately 125 million people worldwide are affected by psoriasis, which accounts for about 2-3% of the global population.
   
• Autoimmune diseases, such as rheumatoid arthritis and psoriasis occur when the immune system mistakenly attacks healthy cells, leading to chronic inflammation and tissue damage.
   
• Cyclosporine, an immunosuppressive drug, is widely used to manage these conditions by modulating immune responses and reducing the activity of overactive immune cells.
   
• As the global incidence of autoimmune diseases continues to rise, fueled by genetic predisposition, environmental triggers, and lifestyle changes, the demand for effective treatment options like cyclosporine is increasing.
   
• Furthermore, advancements in diagnostic techniques are improving early detection rates, further expanding the patient pool requiring cyclosporine therapy and bolstering market growth.
   

Cyclosporine Market Analysis

Based on indication, the global market is segmented into transplant rejection prophylaxis, rheumatoid arthritis, psoriasis, autoimmune myasthenia gravis, dry eye, and other indications. The transplant rejection prophylaxis segment dominated the market and was valued at USD 1.2 billion in 2024.
 

• The transplant rejection prophylaxis segment holds a significant share of the market, driven by its critical role in preventing organ rejection in transplant patients.
   
• Additionally, the high prevalence of organ transplants, such as kidney, liver, and heart transplants, coupled with advancements in surgical techniques and post-transplant care, has contributed to the growing demand for effective prophylactic therapies.
   
• Additionally, the segment benefits from established clinical guidelines that prioritize cyclosporine as a first-line therapy, further solidifying its market dominance.
   

Based on dosage form, the cyclosporine market is categorized into capsule, eye drops, solutions, and creams and ointments. The capsule segment accounted for the highest market share of 31.8% in 2024.
 

• Capsules are preferred over other dosage forms as they provide better patient compliance, especially for long-term therapies required in conditions like organ transplantation and autoimmune diseases.
   
• Furthermore, advancements in encapsulation technologies ensure enhanced bioavailability and stability of cyclosporine, boosting the segment's demand.
   
• The growing prevalence of chronic conditions necessitating immunosuppressive therapies, and the availability of generic capsule formulations have further contributed to the dominance of this segment in the market.
   

Based on route of administration, the market is categorized into oral, topical, and parenteral. The oral segment is anticipated to witness high growth to reach USD 5.5 billion by 2034.
 

• The oral segment holds a significant share in the cyclosporine market, driven by its ease of administration, improved patient compliance, and consistent bioavailability. Oral formulations, such as capsules and oral solutions, are widely preferred for long-term therapy in chronic conditions like organ transplantation and autoimmune diseases, including rheumatoid arthritis and psoriasis.
   
• The segment's dominance is further supported by advancements in drug delivery technologies, ensuring better absorption and reduced side effects.
   

Based on distribution channel, the cyclosporine market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is anticipated to grow at a CAGR of 14.2% between 2025 and 2034.
 

• Hospitals serve as primary centers for organ transplantation procedures, where cyclosporine is a critical component of immunosuppressive therapy to prevent graft rejection. Additionally, the availability of specialized medical teams in hospitals ensures precise dosage and administration, enhancing patient outcomes.
   
• The integration of advanced drug dispensing systems and robust inventory management in hospital pharmacies further supports the accessibility and efficiency of cyclosporine distribution.
   
• This strong alignment with critical healthcare needs and infrastructure cements the dominance of hospital pharmacies in the market.
   

In 2024, the U.S. held a significant position in the North America cyclosporine market and was valued at USD 1.1 billion.
 

• A well-established healthcare infrastructure, high adoption rates of immunosuppressive therapies, and the prevalence of chronic conditions such as autoimmune disorders and organ transplant requirements contribute to the strong market presence.
   
• For instance, approximately 1.3 million adults in the U.S. suffer from rheumatoid arthritis, which represents about 0.6% to 1% of the adult population. Furthermore, approximately 3.0% of U.S. adults aged 20 years and older have psoriasis, translating to over 7.5 million individuals affected.
   
• The presence of major players, extensive research and development activities, and favorable reimbursement policies further bolster the market's growth.
   

Germany shows strong growth potential in the cyclosporine market.
 

• Germany holds a significant position in the Europe market, driven by its robust healthcare infrastructure and advanced pharmaceutical manufacturing capabilities.
   
• Additionally, Germany's aging population and the increasing prevalence of chronic conditions such as organ transplantations and autoimmune diseases contribute to the high demand for immunosuppressive therapies like cyclosporine.
   

The cyclosporine market in Asia Pacific is estimated to grow at a CAGR of 15% over the next few years.
 

• The rising adoption of immunosuppressive therapies, supported by government initiatives and expanding healthcare access, is contributing to market growth.
   
• Additionally, the increasing number of transplant surgeries and advancements in medical technologies in countries such as China, India, and Japan are creating lucrative opportunities for market expansion in the region.
   
• As the demand for effective treatment options rises, the Asia Pacific market is poised for robust growth in the coming years.
   

India presents significant growth potential in the cyclosporine market.
 

• India has significant growth potential in the market, driven by factors such as the increasing prevalence of autoimmune diseases, organ transplantations, and the growing demand for immunosuppressive therapies.
   
• In 2023, India achieved significant milestones in organ transplantation with a total of 18,378 organ transplants.
   
• The growing number of patients requiring long-term immunosuppressive treatment, particularly following organ transplants, is creating substantial market opportunities.
   
• Additionally, India’s cost-effective production of generic cyclosporine also positions it as a key player in both domestic and international markets, further supporting the market's expansion.
   

Brazil's cyclosporine market is projected to witness growth in coming years.
 

• The country's large patient population, coupled with improving access to healthcare services and treatments, is driving the adoption of immunosuppressive therapies like cyclosporine.
   
• Additionally, the government's efforts to improve the healthcare system and regulatory support for pharmaceutical innovations further contribute to the market's growth potential.
   
• With a growing focus on improving treatment options for conditions such as rheumatoid arthritis and psoriasis, Brazil is poised to witness significant growth in the market in the coming years.
   

Cyclosporine Market Share

The competitive landscape in the market is characterized by a mix of established pharmaceutical companies and emerging players, all vying for market share in the immunosuppressant drug segment. Key players include Novartis, with its widely recognized brand Sandimmune, and other firms like Astellas, AbbVie, and Teva, which offer cyclosporine-based products for transplant patients and autoimmune diseases. The market is also seeing increasing competition from generic manufacturers, as patents for several cyclosporine formulations have expired, driving price competition and further intensifying market dynamics.
 

Cyclosporine Market Companies

Few of the prominent players operating in the cyclosporine industry include:

• Avet Pharmaceuticals
• AdvaCare Pharma
• AbbVie
• Apotex
• Cipla
• Dr. Reddy's Laboratories
• Novartis
• Santen Pharmaceutical
• Sun Pharmaceutical Industries
• Strides Pharma Science Limited
• Teva Pharmaceutical Industries
• Viatris
   

Cyclosporine Industry News

• In August 2022, Strides Pharma Science Limited received approval from the U.S. Food and Drug Administration (USFDA) for its Cyclosporine Softgel Capsules USP, available in 25 mg, 50 mg, and 100 mg dosages. This marks a significant milestone as Strides is the first Indian company to gain approval for this product, enhancing its immunosuppressant portfolio in the US market.
   

The cyclosporine market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Indication

• Transplant rejection prophylaxis
• Rheumatoid arthritis
• Psoriasis
• Autoimmune myasthenia gravis
• Dry eye
• Other indications

Market, By Dosage Form

• Capsule
• Eye drops
• Liquid solutions
• Creams and ointments

Market, By Route of Administration

• Oral
• Topical
• Parenteral

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE